ATE5852T1 - Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung. - Google Patents

Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.

Info

Publication number
ATE5852T1
ATE5852T1 AT79302620T AT79302620T ATE5852T1 AT E5852 T1 ATE5852 T1 AT E5852T1 AT 79302620 T AT79302620 T AT 79302620T AT 79302620 T AT79302620 T AT 79302620T AT E5852 T1 ATE5852 T1 AT E5852T1
Authority
AT
Austria
Prior art keywords
compositions
drugs
soluble
increased bioavailability
preparation
Prior art date
Application number
AT79302620T
Other languages
English (en)
Inventor
Frederick Henry Martin
Andrew George Tsuk
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25505864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE5852(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Application granted granted Critical
Publication of ATE5852T1 publication Critical patent/ATE5852T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT79302620T 1978-11-20 1979-11-19 Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung. ATE5852T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96243578A 1978-11-20 1978-11-20
EP79302620A EP0012523B2 (de) 1978-11-20 1979-11-19 Therapeutische Zusammensetzungen mit gesteigerter Bioverfügbarkeit und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
ATE5852T1 true ATE5852T1 (de) 1984-02-15

Family

ID=25505864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT79302620T ATE5852T1 (de) 1978-11-20 1979-11-19 Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.

Country Status (3)

Country Link
EP (1) EP0012523B2 (de)
AT (1) ATE5852T1 (de)
DE (1) DE2966564D1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
EP0179583A1 (de) * 1984-10-04 1986-04-30 Merck & Co. Inc. System zur Verbesserung der Auflösungsgeschwindigkeit in Wasser und der Löslichkeit von schwer löslichen Arzneimitteln
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
GB8629640D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
SE8803935L (sv) * 1988-10-31 1990-05-01 Kabivitrum Ab Laekemedelskomposition
JPH02124894A (ja) * 1988-11-01 1990-05-14 Sanwa Kagaku Kenkyusho Co Ltd フィチン酸安定化組成物
HU204697B (en) * 1988-12-22 1992-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing veterinary composition comprising n-(5-nitrofufurilidene)-3-amino-2-oxazolidone
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
WO1996002234A1 (es) * 1994-07-18 1996-02-01 Luis Cipriano Carvajal Martin Granulos compactos altamente autodisgregantes para uso en formas galenicas conteniendo principios activos insolubles o poco solubles
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
WO1997044014A1 (en) 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
CN1211928A (zh) * 1996-11-04 1999-03-24 联合碳化化学品及塑料技术公司 提高基本不溶于水的化合物溶解度的方法
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US7863331B2 (en) 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
DE10117049A1 (de) * 2001-04-05 2002-10-17 Novartis Ag Zusammensetzung
EP3064198A1 (de) * 2007-09-03 2016-09-07 Nanotherapeutics, Inc. Teilchenzusammensetzung zur abgabe von schwerlöslichen arzneimitteln

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE584726A (de) * 1958-11-17
DE1467938C3 (de) * 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
CA987588A (en) * 1970-01-02 1976-04-20 Sidney Riegelman Solid dispersions of drugs
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
FR2331327A2 (fr) * 1972-01-13 1977-06-10 Sandoz Sa Composition medicamenteuse solide a desagregation rapide
NL7314765A (de) * 1972-10-31 1974-05-02
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
FR2285855A1 (fr) * 1974-09-25 1976-04-23 Kohjin Co Composition therapeutique lyophilisee a base de sel de cyclocytidine et son procede de preparation
US4024240A (en) * 1975-07-18 1977-05-17 Eli Lilly And Company Antibiotic A-32390 compositions
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition

Also Published As

Publication number Publication date
EP0012523A1 (de) 1980-06-25
EP0012523B1 (de) 1984-01-18
EP0012523B2 (de) 1988-02-03
DE2966564D1 (en) 1984-02-23

Similar Documents

Publication Publication Date Title
ATE5852T1 (de) Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
DK0395329T3 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
EP0221041A3 (de) Benzimidazolderivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
SE8402551L (sv) Cinnamoylmoranolin-derivat
SK12993A3 (en) Pharmaceutical composition of florfenicol
JPS6321648B2 (de)
EP0012639A3 (en) Quinolein-3-carboxylic acid derivatives, process for their preparation, their use in medicines and pharmaceutical compositions containing them
IT1153487B (it) Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
ES469878A1 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento del habito de consumir drogas
FI872831A0 (fi) Foerfarande foer framstaellning av farmaceutiska kompositioner.
DE69401502D1 (de) Arzneizubereitung zum Herstellen eines stabilisierten Pulvers das eine Kombination aus Acetylsalicylsäure und Metoclopramid als Wirkstoff enthält
AT382076B (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
ATE25679T1 (de) Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung.
ATE126052T1 (de) System zur gesteuerten freisetzung von wirkstoffen sowie verfahren zu dessen herstellung.
ATE3429T1 (de) Paromomycin-derivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammenzetzung.
IE44030L (en) Ó-amino-ketones.
DE3783923D1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
DE2860724D1 (en) Pseudomonic acid c, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them
US3849558A (en) Pharmaceutical compositions having controlled gastro-intestinal absorption
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt
SE8501312L (sv) Oral doseringsform for etopsid
KR880009943A (ko) 피리다지논 유도체
ES8200363A1 (es) Procedimiento para la obtencion de esteres 4,5-dialquil-3- hidroxi-pirrol-2-carboxilicos
US3962436A (en) Pharmaceutical compositions having controlled rate of gastro-intestinal absorption

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time